MAB Programs 

MacroGenics recently secured $63 million from NIAID and NIH to develop a series of monoclonal antibodies (Mabs) to infectious disease targets which include West Nile Virus (WNV), Smallpox, and H5N1 flu. 

 Click here for more information.

MacroGenics is seeking strategic partners to develop and commercialize MGAWN1.